These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 29764453)

  • 1. AMPA-ergic regulation of amyloid-β levels in an Alzheimer's disease mouse model.
    Hettinger JC; Lee H; Bu G; Holtzman DM; Cirrito JR
    Mol Neurodegener; 2018 May; 13(1):22. PubMed ID: 29764453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors.
    Shemer I; Holmgren C; Min R; Fülöp L; Zilberter M; Sousa KM; Farkas T; Härtig W; Penke B; Burnashev N; Tanila H; Zilberter Y; Harkany T
    Eur J Neurosci; 2006 Apr; 23(8):2035-47. PubMed ID: 16630051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-34a deficiency in APP/PS1 mice promotes cognitive function by increasing synaptic plasticity via AMPA and NMDA receptors.
    Xu Y; Chen P; Wang X; Yao J; Zhuang S
    Neurosci Lett; 2018 Mar; 670():94-104. PubMed ID: 29378298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of growth hormone-releasing hormone on sleep and brain interstitial fluid amyloid-β in an APP transgenic mouse model.
    Liao F; Zhang TJ; Mahan TE; Jiang H; Holtzman DM
    Brain Behav Immun; 2015 Jul; 47():163-71. PubMed ID: 25218899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute inhibition of AMPA receptors by perampanel reduces amyloid β-protein levels by suppressing β-cleavage of APP in Alzheimer's disease models.
    Ueda S; Kuzuya A; Kawata M; Okawa K; Honjo C; Wada T; Matsumoto M; Goto K; Miyamoto M; Yonezawa A; Tanabe Y; Ikeda A; Kinoshita A; Takahashi R
    FASEB J; 2023 Nov; 37(11):e23252. PubMed ID: 37850918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo hippocampal microdialysis reveals impairment of NMDA receptor-cGMP signaling in APP(SW) and APP(SW)/PS1(L166P) Alzheimer's transgenic mice.
    Duszczyk M; Kuszczyk M; Guridi M; Lazarewicz JW; Sadowski MJ
    Neurochem Int; 2012 Dec; 61(7):976-80. PubMed ID: 22841892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life.
    Cirrito JR; May PC; O'Dell MA; Taylor JW; Parsadanian M; Cramer JW; Audia JE; Nissen JS; Bales KR; Paul SM; DeMattos RB; Holtzman DM
    J Neurosci; 2003 Oct; 23(26):8844-53. PubMed ID: 14523085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of Peripheral and Central High Insulin on Brain Insulin Signaling and Amyloid-β in Young and Old APP/PS1 Mice.
    Stanley M; Macauley SL; Caesar EE; Koscal LJ; Moritz W; Robinson GO; Roh J; Keyser J; Jiang H; Holtzman DM
    J Neurosci; 2016 Nov; 36(46):11704-11715. PubMed ID: 27852778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opposing synaptic regulation of amyloid-β metabolism by NMDA receptors in vivo.
    Verges DK; Restivo JL; Goebel WD; Holtzman DM; Cirrito JR
    J Neurosci; 2011 Aug; 31(31):11328-37. PubMed ID: 21813692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Class I HDAC Inhibitor Rescues Synaptic Damage and Neuron Loss in APP-Transfected Cells and APP/PS1 Mice through the GRIP1/AMPA Pathway.
    Han Y; Chen L; Liu J; Chen J; Wang C; Guo Y; Yu X; Zhang C; Chu H; Ma H
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway.
    Gong B; Pan Y; Zhao W; Knable L; Vempati P; Begum S; Ho L; Wang J; Yemul S; Barnum S; Bilski A; Gong BY; Pasinetti GM
    Mol Immunol; 2013 Dec; 56(4):619-29. PubMed ID: 23911420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pimavanserin, a 5HT
    Yuede CM; Wallace CE; Davis TA; Gardiner WD; Hettinger JC; Edwards HM; Hendrix RD; Doherty BM; Yuede KM; Burstein ES; Cirrito JR
    J Neurochem; 2021 Mar; 156(5):658-673. PubMed ID: 33278025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TrkB reduction exacerbates Alzheimer's disease-like signaling aberrations and memory deficits without affecting β-amyloidosis in 5XFAD mice.
    Devi L; Ohno M
    Transl Psychiatry; 2015 May; 5(5):e562. PubMed ID: 25942043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain interstitial oligomeric amyloid β increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease.
    Takeda S; Hashimoto T; Roe AD; Hori Y; Spires-Jones TL; Hyman BT
    FASEB J; 2013 Aug; 27(8):3239-48. PubMed ID: 23640054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRP1 Has a Predominant Role in Production over Clearance of Aβ in a Mouse Model of Alzheimer's Disease.
    Van Gool B; Storck SE; Reekmans SM; Lechat B; Gordts PLSM; Pradier L; Pietrzik CU; Roebroek AJM
    Mol Neurobiol; 2019 Oct; 56(10):7234-7245. PubMed ID: 31004319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses.
    Almeida CG; Tampellini D; Takahashi RH; Greengard P; Lin MT; Snyder EM; Gouras GK
    Neurobiol Dis; 2005 Nov; 20(2):187-98. PubMed ID: 16242627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
    Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
    Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. {beta}-Amyloid impairs AMPA receptor trafficking and function by reducing Ca2+/calmodulin-dependent protein kinase II synaptic distribution.
    Gu Z; Liu W; Yan Z
    J Biol Chem; 2009 Apr; 284(16):10639-49. PubMed ID: 19240035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AMPA receptor activation promotes non-amyloidogenic amyloid precursor protein processing and suppresses neuronal amyloid-β production.
    Hoey SE; Buonocore F; Cox CJ; Hammond VJ; Perkinton MS; Williams RJ
    PLoS One; 2013; 8(10):e78155. PubMed ID: 24205136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.
    Wu G; Miller RA; Connolly B; Marcus J; Renger J; Savage MJ
    Neurodegener Dis; 2014; 14(2):53-66. PubMed ID: 24158021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.